Seek truth from facts, competitive symbiosis
Hunan Zhengqing Pharmaceutical Group Co., Ltd. Special Report on the Deposit and Use of Raised Funds for the First Half of 2020
Category:
Release time:
2020-08-27
Hunan Zhengqing Pharmaceutical Group Co., Ltd.
Regarding Special Report on the Deposit and Use of Raised Funds for the First Half of 2020
|
The Board of Directors and all directors of the Company warrant that there are no false statements, misleading representations, or material omissions in this announcement, and assume legal responsibility for the truthfulness, accuracy, and completeness of its contents. |
Hunan Zhengqing Pharmaceutical Group Co., Ltd. (hereinafter referred to as the "Company") has prepared a special report on the deposit and use of raised funds for the first half of 2020, in accordance with the relevant laws, regulations, and normative documents such as the "Measures for the Supervision and Administration of Non-listed Public Companies".
I. Basic Information on Funds Raised from Targeted Issuance of Shares
The Company's 2019 year The proposal on the Company's first targeted issuance plan for shares in 2019 was reviewed and approved at the third meeting of the sixth session of the Board of Directors on July 27, 2019, and the second extraordinary general meeting of shareholders on August 12, 2019.
The Company ultimately issued 17,964,071 shares to Wu Feichi and Liu Yunjun. shares, with the final issue price per share being RMB 1.67 yuan, and the final total amount of raised funds was 30,000,000.00 yuan. The aforementioned raised funds were fully in place on November 13, 2019, verified by ZhongShen ZhongHuan Certified Public Accountants (Special General Partnership) and issued Capital Verification Report, 众环验字(2019) No. 110005.
II. Deposit and Management of Raised Funds
(I) Deposit of Raised Funds
In accordance with the "Raised Funds Management System," the Company has established a special account for raised funds for this issuance, specifically for the deposit and management of raised funds. The specific account information is as follows:
Account Name: Hunan Zhengqing Pharmaceutical Group Co., Ltd.
Account Bank: China Construction Bank Corporation Huaihua City Branch YinJian Sub-branch
Account Number: 43050172903700000616
(II) Management of Raised Funds
The Company's "Raised Funds Management System" was reviewed and approved at the fourth meeting of the sixth session of the Board of Directors on August 13, 2019. The Company implements special account storage and management for raised funds. In November 2019, the Company, China Construction Bank Corporation Huaihua City Branch YinJian Sub-branch, and CSC Financial Co., Ltd. jointly signed the "Three-Party Supervision Agreement for Raised Funds," opened a special account for raised funds, and transferred all raised funds totaling 30,000,000.00 yuan to the Company's special account for raised funds. The Company strictly abides by the management measures in all aspects of raised fund use, supervision, and accountability, effectively protecting the legitimate rights and interests of the Company and its shareholders.
III. Actual Use of Raised Funds
As of June 30, 2020, the Company's specific use of raised funds for the first half of 2020 is as follows:
|
Item |
Amount (RMB) |
|
I. Balance of raised funds at the end of the last period |
15,906.47 |
|
II. Net amount of interest income after deducting handling fees |
12.06 |
|
III. Amount of usable raised funds |
15,9 18.53 |
|
IV. Use of raised funds - Use for working capital |
15,9 18.53 |
|
V. Account Balance |
0 |
As of 2020 year May 13, the Company in 2019 special funds raised from targeted issuance of shares in the year 30,000,000.00 yuan fully used.
IV. Issues in the Use and Disclosure of Raised Funds
The Company has not changed the purpose of using raised funds during this period, nor has there been any failure to timely, truthfully, accurately, or completely disclose the use of raised funds. There are no illegal or non-compliant circumstances in the deposit, use, management, and disclosure of raised funds.
IV. Conclusive Opinions on the Company's Deposit and Actual Use of Raised Funds
The Company's Board of Directors believes that as of June 30, 2020, the raised funds from this targeted share issuance and their deposit and actual use comply with the provisions of relevant laws, regulations, and normative documents such as the "Measures for the Supervision and Administration of Non-listed Public Companies." There are no instances of irregular deposit of raised funds, nor are there any instances of controlling shareholders, actual controllers, or other related parties occupying or transferring the raised funds from this targeted issuance.
Hunan Zhengqing Pharmaceutical Group Co., Ltd.
Board of Directors
August 27, 2020
Copyright Hunan Zhengqing Pharmaceutical Group Co., Ltd.
Virtual Showroom：
Agent：
OA：
CRM：
在线客服添加返回顶部
右侧在线客服样式 1,2,3 1
图片alt标题设置： Hunan Zhengqing Pharmaceutical Group Co., Ltd.
表单验证提示文本： Please enter correct content!
循环体没有内容时： Updating......
CSS / JS 文件放置地